Study on the Effect of a Beta Blocker on Increased Sensitivity to Pain in Humans Caused by Opioids
Hyperalgesia
About this trial
This is an interventional treatment trial for Hyperalgesia
Eligibility Criteria
Inclusion Criteria:
- Healthy men,
- Age between 18 and 45 years
- Normal weight (according to the table provided by Metropolitan Life Insurance).
Exclusion Criteria:
- Hypersensitivity to opioids or naloxone,
- History of addictive disease,
- Significant cardiac, respiratory, gastrointestinal, neurological, dermatological, and psychiatric diseases,
- Concurrent medication with an analgesic drug,
- Student and employees affiliated with our laboratory
Sites / Locations
- Stanford University School of Medicine
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Propranolol, Then Placebo
Placebo, Then Propranolol
Propranolol, a beta blocker, or placebo to match, will be given to test whether or not it could modulate the expression of remifentanil-induced postinfusion hyperalgesia (RPH) during two pain test including: mechanically evoked pain to map the size of the hyperalgesic skin region caused by electrical stimulation and heat pain.
Propranolol, a beta blocker, or placebo to match, will be given to test whether or not it could modulate the expression of remifentanil-induced postinfusion hyperalgesia (RPH) during two pain test including: mechanically evoked pain to map the size of the hyperalgesic skin region caused by electrical stimulation and heat pain.